Spots Global Cancer Trial Database for A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
Official Title: A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
Study ID: NCT05226507
Interventions
Study Description
Brief Summary: The purpose of the dose escalation phase is to evaluate the safety profile of escalating doses and dose schedules of NXP800. In the expansion phase the preliminary efficacy in subjects with ARID1a mutated ovarian clear cell and ovarian endometrioid cancers will be estimated.
Detailed Description: Part A of the study is a dose escalation by cohort study of NXP800 administered to patients with advanced cancers. The study will identify the maximum tolerated dose (MTD) and propose dose and dose schedules for future studies. In Part B doses selected in Part A are administered to patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Honor Health, Phoenix, Arizona, United States
UC San Diego Health - Moores Cancer Center, La Jolla, California, United States
University of Colorado Cancer Center, Aurora, Colorado, United States
Yale Gynecologic Oncology, New Haven, Connecticut, United States
Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Women's Cancer Care Associates, Albany, New York, United States
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Oklahoma Cancer Specialists and Research Institute, Tulsa, Oklahoma, United States
Oncology Associates of Oregon, Eugene, Oregon, United States
Sidney Kimmel Cancer Center, Asplundh Cancer Pavilion, Willow Grove, Pennsylvania, United States
Texas Oncology, Fort Worth, Texas, United States
University of Virginia Health System, Charlottesville, Virginia, United States
VCU Massey Comprehensive Cancer Center, Richmond, Virginia, United States
Royal Marsden Hospital, London Borough of Sutton, Sutton Surrey, United Kingdom
Addenbrookes Hospital, Cambridge, , United Kingdom
The Beatson West of Scotland Cancer Centre, Glasgow, , United Kingdom
Contact Details
Name: Udai Banerji, Prof
Affiliation: Institute of Cancer Research, Royal Marsden Foundation Trust
Role: PRINCIPAL_INVESTIGATOR
Name: Susana Banerjee, Dr
Affiliation: Institute of Cancer Research, Royal Marsden NHS Foundation Trust
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
